# EDGAR Filing Document

**Accession Number:** 0002017423
**File Stem:** 0001140361-26-008905
**Filing Date:** 2026-3
**Character Count:** 10336
**Document Hash:** a1eb15c892c86a684db5926bfebc5c10
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-008905.hdr.sgml**: 20260310

**ACCESSION NUMBER**: 0001140361-26-008905

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260306

**FILED AS OF DATE**: 20260310

**DATE AS OF CHANGE**: 20260310

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Kestenberg-Messina Kaitlin M.
- **CENTRAL INDEX KEY:** 0002017423

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36728
- **FILM NUMBER:** 26741311

**MAIL ADDRESS:**
- **STREET 1:** 5800 PARK OF COMMERCE BLVD. NW,
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33487
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ADMA BIOLOGICS, INC.
- **CENTRAL INDEX KEY:** 0001368514
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 562590442
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** C/O ADMA BIOLOGICS, INC.
- **STREET 2:** 465 STATE ROUTE 17
- **CITY:** RAMSEY
- **STATE:** NJ
- **ZIP:** 07446
- **BUSINESS PHONE:** (201) 478-5552

**MAIL ADDRESS:**
- **STREET 1:** C/O ADMA BIOLOGICS, INC.
- **STREET 2:** 465 STATE ROUTE 17
- **CITY:** RAMSEY
- **STATE:** NJ
- **ZIP:** 07446

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** R&R ACQUISITION VI, INC
- **DATE OF NAME CHANGE:** 20060707

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Kestenberg-Messina Kaitlin M.<br><sub>(Last) (First) (Middle)</sub><br>C/O ADMA BIOLOGICS, INC.<br>5800 PARK OF COMMERCE BLVD. NW,<br><sub>(Street)</sub><br>BOCA RATON, FL 33487<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-06 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_COO and SVP, Compliance_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>ADMA BIOLOGICS, INC. [ ADMA ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-03-06 |  | F |  | 10059<sup>(1)</sup> | D | $15.39 | 562101 | D |  |
| Common Stock | 2026-03-07 |  | F |  | 4235<sup>(1)</sup> | D | $15.39 | 557866 | D |  |
| Common Stock | 2026-03-09 |  | J<sup>(2)</sup> |  | 91266 | D | $0 | 466600 | D |  |
| Common Stock | 2026-03-09 |  | M |  | 2500 | A | $5 | 469100 | D |  |
| Common Stock | 2026-03-09 |  | M |  | 1250 | A | $4.31 | 470350 | D |  |
| Common Stock | 2026-03-09 |  | M |  | 2646 | A | $2.83 | 472996 | D |  |
| Common Stock | 2026-03-09 |  | M |  | 1525 | A | $2.35 | 474521 | D |  |
| Common Stock | 2026-03-09 |  | M |  | 2175 | A | $1.55 | 476696 | D |  |
| Common Stock | 2026-03-09 |  | S |  | 10096<sup>(3)</sup> | D | 15.63<sup>(4)</sup> | 466600<sup>(5)(6)</sup> | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | $5 | 2026-03-09 |  | M |  |  | 2500 | <sup>(7)</sup> | 2027-02-14 | Common Stock | 2500 | $0 | 2500 | D |  |
| Stock Option (right to buy) | $4.31 | 2026-03-09 |  | M |  |  | 1250 | <sup>(8)</sup> | 2029-06-05 | Common Stock | 1250 | $0 | 1250 | D |  |
| Stock Option (right to buy) | $2.83 | 2026-03-09 |  | M |  |  | 2646 | <sup>(9)</sup> | 2030-08-19 | Common Stock | 2646 | $0 | 2771 | D |  |
| Stock Option (right to buy) | $2.35 | 2026-03-09 |  | M |  |  | 1525 | <sup>(10)</sup> | 2031-02-25 | Common Stock | 1525 | $0 | 2225 | D |  |
| Stock Option (right to buy) | $1.55 | 2026-03-09 |  | M |  |  | 2175 | <sup>(11)</sup> | 2031-07-19 | Common Stock | 2175 | $0 | 2825 | D |  |

---

### Footnotes:

(1) Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

(2) The shares were transferred by the reporting person in accordance with the terms of a court-approved divorce settlement agreement (the "Divorce Settlement").

(3) The securities were sold by the Reporting Person in accordance with the terms of the Divorce Settlement.

(4) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.59 to $15.65, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

(5) Includes, as of the transaction date (i) 91,631 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 58,338 unvested RSUs out of 77,784 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 144,240 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date;

(6) (continued from footnote 5) (iv) 15,000 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (v) 23,750 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; and (vi) 133,641 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

(7) The incentive stock options were granted to the Reporting Person on February 14, 2017, and are fully vested.

(8) The incentive stock options were granted to the Reporting Person on June 5, 2019, and are fully vested.

(9) The incentive stock options were granted to the Reporting Person on August 19, 2020, and are fully vested.

(10) The incentive stock options were granted to the Reporting Person on February 25, 2021, and are fully vested.

(11) The incentive stock options were granted to the Reporting Person on July 19, 2021, and are fully vested.

**Signature:** /s/ Kaitlin M. Kestenberg-Messina, by Michael A. Goldstein as Attorney-in-fact  
**Date:** 2026-03-10

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**